Shots:
- PulseSight has presented the P-I (PST-611-CT1) trial data assessing two dose levels (low and high) of PST-611 in two successive dose groups involving 6 pts with late-stage dry AMD/Geographic Atrophy, with a 16wk. follow-up, at ARVO 2026
- Trial met its 1 & 2EPs, showing favorable safety & tolerability, along with stable BCVA, no SAEs/SUSARs or intraocular inflammation, while early efficacy signals incl. patient-reported vision improvements & reduced GA lesion growth beyond follow-up in 1 case
- Following P-I results, PulseSight submitted a CTA to France’s ANSM to assess 3 administrations of PST-611 (high dose) in a 52wk. repeat-dose P-IIa (PST-611-CT2) trial (n=~20) across 3 sites, with initiation expected in H2’26 & results anticipated in 2028, subject to approval
Ref: PulseSight | Image: PulseSight | Press Release
Related News: PulseSight Therapeutics Reports First Patient Dosing with PST-611 in P-I (PST-611-CT1) Trial for Dry AMD/Geographic Atrophy
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
